A Study of Neuron-Specific Enolase as Potential Biomarker for Assessing the Severityand Outcome in Patients with Acute Ischaemic Stroke (original) (raw)
Related papers
International Journal of Biomedical Research, 2015
Objectives: The aim of this study is to see the role of serum NSE (Neuron Specific Enolase) as a neuronal damage marker and in differentiating the side of brain lesion in acute ischemic stroke patients. Methods: A total of 35 acute ischemic stroke patients (clinically and radiologically confirmed) irrespective of age and sex, admitted in Emergency Unit, Medicine Department within 24 hours of stroke onset were included in this study. Plain CT scan or MRI brain was done for all these patients on admission and after 48 hours to confirm the diagnosis and the side of the lesion in brain. Serum NSE was estimated by using NSE Human ELISA Kit, in the Department of Physiology. Results: In this study, serum NSE bears a positive significant correlation to the infarct volume in brain (r=0.783, p<0.001) and to the National Institute of Health Stroke Scale (NIHSS) (r=0.538, p=0.001). However, there is no significance difference between the serum NSE in right hemispheric brain lesion compared to left hemispheric brain lesion (p=0.596). Conclusions: Serum NSE within 24 hours of stroke onset can reflect the volume of brain lesion and severity of acute stroke but cannot differentiate the side of brain lesion in these patients.
International Journal of Research in Medical Sciences, 2016
Background: Neuronal specific Enolase (NSE) is the neuronal form of the glycolytic enzyme enolase. This study has been conducted to see the role of serum NSE in differentiating the side of brain lesion within 24 hours of acute hemorrhagic stroke onset. Methods: The study was conducted in collaboration with the Department of Physiology and Medicine after Ethical clearance from December 2013 to April 2015. Our study group consists of 35 acute hemorrhagic stroke patients (clinically and radio logically confirmed) irrespective of age and sex, admitted in Emergency Unit, Medicine Department within 24 hours of stroke symptom onset. The patients were undergone plain CT scan brain on admission to confirm the diagnosis and the side of the lesion in brain. Serum NSE for these patients was estimated by using NSE Human ELISA Kit, in the Department of Physiology. Results: In this study, serum NSE bears a positive significant correlation to the hematoma volume in brain (r=0.786, p<0.001) and to the National Institute of Health Stroke Scale (NIHSS) (r=0.44, p=0.008). However, there is no significance difference between the serum NSE in right hemispheric brain lesion compared to left hemispheric brain lesion (p=0.597). Conclusions: Serum NSE within 24 hours of stroke onset can reflect the volume of brain lesion and severity of neurological deficit but cannot differentiate the side of brain lesion in these patients.
A study on Neuron Specific Enolase (NSE) in cerebrovascular stroke patients
Annals of International medical and Dental Research
Background: Biochemical markers of acute neuronal injury may aid in the diagnosis and management of cerebrovascular stroke. Neuron specific enolase (NSE) is one such marker which is released in the blood in acute neuronal injury and can be estimated in the serum of patients to assess the short-term neurological outcome. This study was carried out on patients of acute cerebrovascular stroke with the aim to compare NSE levels in normal subjects with that in cerebrovascular stroke patients. Methods: 60 subjects investigated in the study included 30 cerebrovascular stroke patients who were admitted within 72 hours of onset of stroke symptoms, in the Emergency Department and the Department of Neurology at HIMS, and 30 healthy controls. Serum NSE levels of cases and controls were determined on day 1 and day 7 using DRG-NSE ELISA kit. Statistical analysis was performed using the unpaired 't' test on SPSS software for windows version 17.0 Results: There was a significant difference in the levels of serum NSE between cases and controls (p<0.001).The mean levels of serum NSE in controls were 2.25±2.12 ng/ml and in cases at the time of admission were 89.18±46.89 ng/ml. The normal range of serum NSE is 0-12 ng/ml. It was also observed that the levels of serum NSE showed no difference in males or females or among different age groups. Conclusion: This study showed that estimation of serum NSE levels can be used as an early marker of neuronal damage in acute cerebrovascular stroke patients.
Annals of Indian Academy of Neurology, 2013
Bаckground: Stroke is defined аs а sudden onset of а neurologicаl deficit cаused by аn аcute focаl injury to the centrаl nervous system due to а vаsculаr cаuse. NSE is releаsed into the cerebrospinаl fluid аnd blood, in response to different forms of brаin injury, including ischemic stroke, аnd cаn serve аs а peripherаl indicаtor of the ongoing neuronаl dаmаge. This present study аims to investigаte the correlаtion between neuron-specific enolаse аnd serum glucose level in pаtients with аcute ischemic stroke аt the time of аdmission. Pаtients аnd Methods: We investigаted 49 pаtients with complete stroke who were аdmitted to Criticаl Cаre Depаrtment аnd Stroke Depаrtment of Hue Centrаl Hospitаl. NSE wаs meаsured with commerciаlly аvаilаble quаntitаtive 'sаndwich' enzyme-linked immunosorbent аssаy kits obtаined from R аnd D Systems. Hyperglycemiа wаs defined аs blood glucose concentrаtion ≥ 7 mmol / L, аnd meаsured using the glucose oxidаse method immediаtely. Results: Significаntly increаsed NSE levels were found in ischemic stroke pаtients аs compаred to the control. Hyperglycemic ischemic stroke pаtients hаd increаsed levels of NSE, аnd Nаtionаl Institute of Heаlth stroke scаle scores (NIHSS score) compаred to normoglycemic ischemic stroke pаtients. In аddition the serum NSE level of hyperglycemic stroke pаtients wаs аlso positively correlаted with the serum glucose (r = 0.673 P < 0.01). Conclusion: Hyperglycemiа predicts аn increаsed risk of poor outcome аfter ischemic stroke аnd it is reflected by а significаntly increаsed level of Neuron-Specific Enolаse.
The Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2021
Background: Biological markers of acute nerve cell damage can assist in the outcome of acute ischemic stroke, such as neuron-specific enolase (NSE) that have been tested for association with initial severity of stroke, extent of infarction, and functional outcome. Objective: To determine short-term prognostic value of the biochemical marker neuron-specific enolase (NSE) in acute ischemic stroke. Methods: A cohort study carried out on 37 patients with acute ischemic stroke. Data were gathered in a prepared data sheet. Initial serum NSE level was measured to the patients in the Emergency department within 6 h of the onset of stroke and another measurement after 48 h. National Institute of Health Stroke Scale (NIHSS) was held to the patients at presentation and after 28 days of stroke to determine short-term morbidity and mortality. Results: Out of the 37 patients, 31 patients survived (no-death group) and 6 patients died (death group). The mean serum level of neuron-specific enolase at presentation and after 48 h was significantly higher in the death group than in the no-death group. There was a statistically significant positive correlation between neuron-specific enolase (NSE) serum level and clinical severity of stroke (NIHSS) among the patients at presentation (r = 0.737, p = 0.000). Conclusion: Neuron-specific enolase (NSE) can be applied as single independent marker for prediction of mortality and short-term morbidity in ischemic stroke patients.
Journal of Clinical Neuroscience, 2005
Our goal was to determine the neuron-specific enolase (NSE) concentration in cerebrospinal fluid (CSF) and plasma in patients with the acute brain infarction (BI) and analyze the correlation between the measured NSE concentration and infarct volume and the degree of neurological and functional deficit. The study included 55 patients aged 56-68 with BI in the acute phase. The control group consisted of 16 patients subjected to diagnostic radiculography. The results showed a significant increase of NSE concentration within the first seven days in patients compared to the controls (2.838 +/- 0.504 ng/ml CSF and 4.479 +/- 0.893 ng/ml plasma). A significant correlation was found between NSE concentration and infarction volume and the degree of neurological and functional deficit both in the CSF (r = 0.828, r = 0.735, r = 0.796; p < 0.001) and in plasma (r = 0.810, r = 0.681, r = 0.783; p < 0.001). The results suggest that an early determination of this marker in CSF and plasma in patients with BI could be a valuable diagnostic factor.
International Clinical Neuroscience Journal
Background: We aim to assess the predictive value of serum neuron-specific enolase (NSE) level in patients with acute ischemic stroke referring to the emergency department. Methods: This systematic review and meta-analysis performed, considering the PRISMA and MOOSE statement guidelines. A computerized literature search of the known medical database conducted by using the relevant keywords. We included studies published before November 2016 in which stroke patients compared with non-stroke controls and also studies evaluating the serum levels of NSE in the study groups. Statistical analysis was pooled in a random effect model analysis using the Comprehensive Meta-Analysis software. Results: We included 12 articles in the qualitative and quantitative analysis, that their quality acceptable based on the Newcastle Ottawa Scale (NOS scale). The pooled effect estimates showed that NSE is significantly higher in ischemic stroke patients in comparison with their controls with a high effect...
2019
Original Research Article Cerebrovascular stroke remains largely a clinical diagnosis. The use of biomarkers in diagnosing stroke and assessing prognosis is an emerging and rapidly evolving field. Neuron Specific Enolase (NSE) is mentioned as a possible reliable marker of neuronal tissue damage. It is released from neurons after infarction. High levels of serum NSE is correlated with worse clinical outcome. This study is aimed to investigate the difference in level of serum neuron specific enolase within 72 hours of stroke in hyperglycemic and normoglycemic ischemic stroke patients with left middle cerebral artery infarct and its correlation with NIHSS score & modified Rankin scale. This cross-sectional study was conducted in tertiary health care. Newly diagnosed cases of 25 hyperglycemic (FBS > 126mg/dl) and 25 normoglycemic (FBS< 126mg/dl) ischemic stroke patients (diagnosed by CT scan, clinical signs &symptoms) within the age group of 22 to 86 years of both sexes were inclu...
Clinical Chemistry and Laboratory Medicine, 2000
Background: The blood-brain barrier is compromised in patients with stroke. The release of neuro-biochemical protein markers, such as neuron specific enolase (NSE) into the circulation may allow the pathophysiology and prognosis of patients with cerebrovascular diseases to be evaluated further. The present study was designed to measure the marker of neuronal damage, NSE, in saliva and serum of patients with acute ischemic stroke and patients with stroke related diseases as a diagnostic and/or monitoring tool for early prediction of ischemic stroke. Methods: Salivary and serum NSE concentrations were measured in 150 individuals. Fifty were patients recently diagnosed as having ischemic stroke, 75 were gender and age-matched risk-group patients (patients with hypertension, type 2 diabetes and ischemic heart disease). Another 25 were gender and age-matched healthy controls. Results: Salivary and serum NSE concentrations were significantly higher than that of healthy controls. The cutoff threshold for salivary NSE of 3.7 mg/L was optimum, showing 80% accuracy for differentiation of ischemic stroke from normal individuals. Conclusions: Salivary NSE (alone or in combination with serum) can be used as a valuable diagnostic and possibly prognostic tool for measurement of neuronal damage in patients with stroke and stroke-related diseases.
Clinical Chemistry and Laboratory Medicine, 2009
Background: Neuron-specific enolase (NSE) and S100 protein are implicated in several brain injuries, including stroke. Our objective was to analyze the temporal profile and the clinical significance of NSE and S-100 in acute ischemic (IS) and intracerebral hemorrhage (ICH). Methods: We studied 224 patients with IS and 44 patients with ICH. Computerized tomography (CT) scans were performed to assess infarct volume. Stroke severity was evaluated using the National Institute of Health Stroke Scale (NIHSS), and functional outcome at 3 months with the modified Rankin Scale (mRS). Serum NSE and S100 protein were measured using an electrochemiluminescenceimmunoassay. Results: Peak values were found at 72 h for NSE and at 24 h for S100 in IS. For ICH, peak values were found at 24 h for both NSE and S100. At these time intervals S100 and NSE correlated with the NIHSS score and were independently associated with poor outcome. Conclusions: High serum NSE and S100 are associated with poor outcome in IS, and high serum NSE is associated with poor outcome in ICH. These findings suggest the potential utility of NSE and S100 as prognostic markers for acute stroke. Clin Chem Lab Med 2009;47:1513-8.